"Semaglutide and Wegovy: Promising Heart Health Benefits Unveiled in New Studies"

Semaglutide, the active ingredient in weight loss drugs like Wegovy and Ozempic, has been found to reduce the risk of heart attacks and strokes by 20% in overweight individuals with pre-existing cardiovascular disease but without Type 2 diabetes, according to a study of over 17,000 people. Semaglutide, initially prescribed for Type 2 diabetes, has gained attention for its role in weight loss. The drug works by slowing down food movement in the stomach and curbing appetite. Researchers believe that semaglutide may also reduce inflammation and promote plaque stability in arteries, leading to cardio protective effects when combined with weight loss.